이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

An Evaluation of the Potential for VH4011499 Drug-drug-interactions

2026년 11월 9일 업데이트: ViiV Healthcare

A Phase 1, Open-label Study to Evaluate the Potential for VH4011499 Drug-drug-interactions in HIV Negative Adult Participants

The purpose of this study is to evaluate the pharmacokinetic (PK) interactions between VH4011499 and representative drugs containing inhibitors and inducers, selected transporters, and statins, in HIV negative adults. The study will also assess to assess safety and tolerability during co-administration of VH4011499 with the selected drugs.

연구 개요

연구 유형

중재적

등록 (추정된)

75

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Participants must be 18 to 60 years of age inclusive at the time of signing the informed consent form (ICF).

  • Male or female:

    1. Male Participants:

      No restrictions for male participants.

    2. A female participant (female sex assigned at birth) is eligible to participate if:

They are a woman of non-child bearing potential (WONCBP). There is no requirement for female study participants to use a highly effective method of contraception since, to be eligible, they must be of nonchildbearing potential.

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, cardiac monitoring, and clinical laboratory evaluations at Screening.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • History or presence of clinical condition or disorder that could be capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drugs, interfering with the interpretation of data or would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
  • Pre-existing clinically relevant, gastro-intestinal pathology or diagnosis.
  • A history, or current abnormality in glucose metabolism requiring concomitant use of insulin or other medications for glucose control.
  • Clinically significant abnormal blood pressure at Screening.
  • Lymphoma, leukemia, or any malignancy within the past 5 years (with specified exceptions) or breast cancer within the past 10 years.
  • Breast cancer within the past 10 years.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities, or history of hepatic porphyria.
  • History of syncope, clinically significant palpitations, cardiac arrhythmias or other cardiac diseases or a family and personal history of long QT syndrome.
  • History of seizure(s) and / or other clinically significant neurological conditions.
  • Pre-existing psychiatric condition, that would pose a safety risk to the participant or interfere with participation in the study.
  • Participants with any history of any drug hypersensitivity, delayed-type hypersensitivity, or severe hypersensitivity reactions, as well as history of sensitivity to the study interventions.
  • Participant is mentally or legally incapacitated.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Participants who are carriers of the HLA-B*15:02 and/or HLA-A*31:01 gene.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: History of bone marrow depression, aplastic anemia, agranulocytosis, or other clinically significant hematologic or bone marrow disorder.
  • Unable to refrain from the use of prescription or non-prescription medications.
  • Use of monoamine oxidase inhibitors (MAOIs) within 14 days prior to Day -1.
  • Cohort 3:VH4011499 + Carbamazepine ONLY: Known hypersensitivity to carbamazepine, oxcarbazepine, or tricyclic compounds.
  • Exposure to more than 4 new investigational products within 12 months prior to the first dosing day.
  • Current enrollment or past participation in another investigational study in which an investigational intervention, within the protocol-defined exclusion period.
  • Participant has donated or lost blood, or has donated plasma within 30 days prior to first administration.
  • Current enrollment or past participation in this clinical study.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
  • eGFR <90 mL/min or serum creatinine >1.1× upper limit of normal (ULN) .
  • Hemoglobin <12.5 g/dL for men and <11 g/dL for women.
  • Participants with active hepatitis B virus (HBV) based on any of the following are excluded: 1) Positive hepatitis B surface antigen (HBsAg), 2) Positive hepatitis B surface antibody (HBcAb) except HBV DNA is negative.
  • Positive Hepatitis C antibody test result at Screening.
  • Positive pre-study drug/alcohol screen.
  • Positive HIV-1 antibody / antigen fourth generation test (point of care test or laboratory immunoassay) and / or acute viral symptoms with no alternative etiology within 3 weeks prior to Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Clinically significant hematologic abnormalities at Screening.
  • Cohort 3: VH4011499 + Carbamazepine ONLY: Serum sodium <135 millimole/L.
  • Regular alcohol consumption within 6 months prior to Screening.
  • Regular use of known drugs of abuse.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to Screening and at admission.
  • Sensitivity to the study drugs, or components thereof, or other drug or other allergy that, contraindicates participation in the study.
  • Prior exposure to VH4011499 or Lenacapavir in any formulation..
  • Study participants with ALT >1.0x ULN or total bilirubin >1.5x ULN are excluded at Screening.
  • Any significant arrhythmia or ECG findings meeting protocol-defined exclusion criteria.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1: VH4011499 + Ritonavir

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-54, participants receive Ritonavir twice daily. On Day 26, participants receive another single dose of VH4011499, along with Ritonavir.

VH4011499 is administered to the participants based on the protocol schedule.

Ritonavir is administered to the participants based on the protocol schedule.

실험적: Cohort 2: VH4011499 + Efavirenz

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-58, participants receive Efavirenz once daily. On Day 37, participants receive another single dose of VH4011499, along with Efavirenz.

VH4011499 is administered to the participants based on the protocol schedule.

Efavirenz is administered to the participants based on the protocol schedule.

실험적: Cohort 3: VH4011499 + Carbamazepine

Participants receive a single dose of VH4011499 at Day 1, followed by a 21-day washout period. On days 23-25, participants receive Carbamazepine low dose; on days 26-28, they receive Carbamazepine medium dose; and on days 29-62, they receive Carbamazepine high dose. On Day 41, the participants receive another single dose of VH4011499, along with Carbamazepine high dose.

VH4011499 is administered to the participants based on the protocol schedule.

Carbamazepine is administered to the participants based on the protocol schedule.

실험적: Cohort 4: VH4011499 + Metformin + Digoxin

Participants receive a dose of Metformin and Digoxin on Day 1, followed by a 14-day washout period. On days 10-24, participants receive VH4011499 once daily (a higher dose on Day 10, followed by a lower dose on days 11-24). On Day 16, participants receive another dose of Metformin and Digoxin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Metformin is administered to the participants based on the protocol schedule.

Digoxin is administered to the participants based on the protocol schedule.

실험적: Cohort 5: VH4011499 + Rosuvastatin + Pitavastatin

Participants receive a dose of Rosuvastatin on Day 1, and a dose of Pitavastatin on Day 5, followed by a 10-day washout period. On days 11-26, participants receive VH4011499 once daily (a higher dose on Day 11, followed by a lower dose on days 12-26). On Day 17, participants receive another dose of Pitavastatin, and on Day 22 they receive another dose of Rosuvastatin, along with VH4011499.

VH4011499 is administered to the participants based on the protocol schedule.

Rosuvastatin is administered to the participants based on the protocol schedule.

Pitavastatin is administered to the participants based on the protocol schedule.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Maximum plasma concentration (Cmax) of VH4011499 when administered alone
기간: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Cmax of VH4011499 when co-administered with Ritonavir
기간: Day 26
Day 26
Cmax of VH4011499 when co-administered with Efavirenz
기간: Day 37
Day 37
Cmax of VH4011499 when co-administered with Carbamazepine
기간: Day 41
Day 41
Area under the concentration-time curve from 0 to tau [AUC(0-t)] of VH4011499 when administered alone
기간: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-t) of VH4011499 when co-administered with Ritonavir
기간: Day 26
Day 26
AUC(0-t) of VH4011499 when co-administered with Efavirenz
기간: Day 37
Day 37
AUC(0-t) of VH4011499 when co-administered with Carbamazepine
기간: Day 41
Day 41
Area under the concentration-time curve from 0 to infinity [AUC(0-inf)] of VH4011499 when administered alone
기간: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
AUC(0-inf) of VH4011499 when co-administered with Ritonavir
기간: Day 26
Day 26
AUC(0-inf) of VH4011499 when co-administered with Efavirenz
기간: Day 37
Day 37
AUC(0-inf) of VH4011499 when co-administered with Carbamazepine
기간: Day 41
Day 41
Cmax of Metformin when administered alone
기간: Day 1
Day 1
Cmax of Metformin when co-administered with VH4011499
기간: Day 16
Day 16
AUC(0-t) of Metformin when administered alone
기간: Day 1
Day 1
AUC(0-t) of Metformin when co-administered with VH4011499
기간: Day 16
Day 16
AUC(0-inf) of Metformin when administered alone
기간: Day 1
Day 1
AUC(0-inf) of Metformin when co-administered with VH4011499
기간: Day 16
Day 16
Cmax of Digoxin when administered alone
기간: Day 1
Day 1
Cmax of Digoxin when co-administered with VH4011499
기간: Day 16
Day 16
AUC(0-t) of Digoxin when administered alone
기간: Day 1
Day 1
AUC(0-t) of Digoxin when co-administered with VH4011499
기간: Day 16
Day 16
AUC(0-inf) of Digoxin when administered alone
기간: Day 1
Day 1
AUC(0-inf) of Digoxin when co-administered with VH4011499
기간: Day 16
Day 16
Cmax of Rosuvastatin when administered alone
기간: Day 5
Day 5
Cmax of Rosuvastatin when co-administered with VH4011499
기간: Day 22
Day 22
AUC(0-t) of Rosuvastatin when administered alone
기간: Day 5
Day 5
AUC(0-t) of Rosuvastatin when co-administered with VH4011499
기간: Day 22
Day 22
AUC(0-inf) of Rosuvastatin when administered alone
기간: Day 5
Day 5
AUC(0-inf) of Rosuvastatin when co-administered with VH4011499
기간: Day 22
Day 22
Cmax of Pitavastatin when administered alone
기간: Day 1
Day 1
Cmax of Pitavastatin when co-administered with VH4011499
기간: Day 17
Day 17
AUC(0-t) of Pitavastatin when administered alone
기간: Day 1
Day 1
AUC(0-t) of Pitavastatin when co-administered with VH4011499
기간: Day 17
Day 17
AUC(0-inf) of Pitavastatin when administered alone
기간: Day 1
Day 1
AUC(0-inf) of Pitavastatin when co-administered with VH4011499
기간: Day 17
Day 17

2차 결과 측정

결과 측정
측정값 설명
기간
Number of participants with adverse events (AEs), overall and by grade.
기간: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of AEs is reported based on the Division of acquired immunodeficiency syndrome (DAIDS) grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with AEs leading to study treatment discontinuation
기간: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with change from baseline in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
기간: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Number of participants with maximum toxicity grade increase in alanine transaminase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), direct bilirubin and total bilirubin
기간: Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.

The toxicity is reported based on DAIDS grading scale, where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=potentially life-threatening, Grade 5=death.

Days 1 to 55 for VH4011499+Ritonavir Group; Days 1 to 59 for VH4011499+Efavirenz Group; Days 1 to 66 for VH4011499+Carbamazepine Group; Days 1 to 44 for VH4011499+Metformin+Digoxin Group; Days 1 to 44 for VH4011499+Rosuvastatin+Pitavastatin Group.
Time to maximum plasma concentration (Tmax) of VH4011499 when administered alone.
기간: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
Tmax of VH4011499 when co-administered with Ritonavir
기간: Day 26
Day 26
Tmax of VH4011499 when co-administered with Efavirenz
기간: Day 37
Day 37
Tmax of VH4011499 when co-administered with Carbamazepine
기간: Day 41
Day 41
Apparent oral clearance (CL/F) of VH4011499 when administered alone
기간: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
CL/F of VH4011499 when co-administered with Ritonavir
기간: Day 26
Day 26
CL/F of VH4011499 when co-administered with Efavirenz
기간: Day 37
Day 37
CL/F of VH4011499 when co-administered with Carbamazepine
기간: Day 41
Day 41
Apparent terminal half-life (t1/2) of VH4011499 when administered alone
기간: Day 1 for Cohorts 1, 2 and 3
Day 1 for Cohorts 1, 2 and 3
t1/2 of VH4011499 when co-administered with Ritonavir
기간: Day 26
Day 26
t1/2 of VH4011499 when co-administered with Efavirenz
기간: Day 37
Day 37
t1/2 of VH4011499 when co-administered with Carbamazepine
기간: Day 41
Day 41
Cmax of VH4011499 when co-administered with Metformin and Digoxin
기간: Day 16
Day 16
AUC(0-t) of VH4011499 when co-administered with Metformin and Digoxin
기간: Day 16
Day 16
AUC(0-inf) of VH4011499 when co-administered with Metformin and Digoxin
기간: Day 16
Day 16
Cmax of Ritonavir when co-administered with VH4011499
기간: Day 26
Day 26
AUC(0-t) of Ritonavir when co-administered with VH4011499
기간: Day 26
Day 26
AUC(0-inf) of Ritonavir when co-administered with VH4011499
기간: Day 26
Day 26
Cmax of Efavirenz when co-administered with VH4011499
기간: Day 37
Day 37
AUC(0-t) of Efavirenz when co-administered with VH4011499
기간: Day 37
Day 37
AUC(0-inf) of Efavirenz when co-administered with VH4011499
기간: Day 37
Day 37
Cmax of Carbamazepine when co-administered with VH4011499
기간: Day 41
Day 41
AUC(0-t) of Carbamazepine when co-administered with VH4011499
기간: Day 41
Day 41
AUC(0-inf) of Carbamazepine when co-administered with VH4011499
기간: Day 41
Day 41
Cmax of VH4011499 when co-administered with Rosuvastatin
기간: Day 22
Day 22
AUC(0-t) of VH4011499 when co-administered with Rosuvastatin
기간: Day 22
Day 22
AUC(0-inf) of VH4011499 when co-administered with Rosuvastatin
기간: Day 22
Day 22
Cmax of VH4011499 when co-administered with Pitavastatin
기간: Day 17
Day 17
AUC(0-t) of VH4011499 when co-administered with Pitavastatin
기간: Day 17
Day 17
AUC(0-inf) of VH4011499 when co-administered with Pitavastatin
기간: Day 17
Day 17

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 16일

기본 완료 (추정된)

2027년 3월 12일

연구 완료 (추정된)

2027년 3월 12일

연구 등록 날짜

최초 제출

2026년 11월 9일

QC 기준을 충족하는 최초 제출

2026년 11월 9일

처음 게시됨 (실제)

2026년 11월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 9일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

IPD 공유 기간

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD 공유 액세스 기준

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다